Survival in adolescents and young adults (AYAs, ages 15-40 years) undergoing myeloablative HCT for acute lymphoblastic leukemia (ALL) has improved over time, according to study data from 2,668 transplant recipients reported to the CIBMTR. The study analyzed transplant outcomes in 981 children, 1,218 AYAs, and 469 older adults during three time periods: 1990-1995, 1996-2001, and 2002-2007. Survival improved significantly over time in AYAs, which paralleled the improved survival seen in children, but overall survival did not change over time for older adults. The researchers noted that "survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era."
Wood WA, et al. Biol Blood Marrow Transplant